Dr. Terry Heiman-Patterson Discusses Phase 2 Clinical Trial Results for ALS Treatment

Terry Heiman-Patterson, MD, Professor of Neurology at the Lewis Katz School of Medicine at Temple University, spoke with PhillyVoice about the results of the phase 2 trial for AMX0035, a treatment for amyotrophic lateral sclerosis (ALS) that combines two existing drugs, sodium phenylbutyrate and tauroursodeoxycholic acid, to target two different facets of the disease’s progression. Dr. Heiman-Patterson was the principal investigator at Temple.